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ABSTRACT
Airway hypersensitivity is routinely evaluated by measuring the
concentration (PC20) of inhaled methacholine or histamine that
causes a 20% fall in forced expiratory volume in 1 second (FEV1).
It has been suggested that a percentage fall in forced vital capacity
(FVC) measured at the PC20 dose of inhaled agonist (FVC) is a
potentially useful clinical measure in patients who have asthma
because it provides indirect information about gas trapping and
therefore the maximal airway response. The relationships between
serum eosinophil cationic protein (ECP) levels and the maximal
airway response or FVC are largely unknown. The aims of this
study were to determine whether FVC is correlated with the
degree of maximal airway response and to examine the relation-
ships between serum ECP and FVC or maximal airway response
in patients who have mild asthma. Fifty-eight patients with mild
asthma underwent high-dose methacholine challenge testing. The
PC20, maximal airway response, and FVC were measured on the
methacholine dose–response curves. Serum ECP levels also were
determined. Subjects without a maximal response plateau (n  33)
had a significantly higher level of FVC (17.9  4.1%) than
subjects with a plateau (n  25; 14.9  4.8%). A significant
correlation was found between FVC and the level of maximal
response plateau (r  0.446; p  0.026). Not only methacholine
PC20 but also maximal airway response or FVC had no rela-
tionships with serum ECP levels. Our results suggest that FVC
can be used as a surrogate marker of maximal airway response in
patients who have mild asthma and that neither maximal airway
response nor FVC reflects blood eosinophil activation any
more than methacholine PC20. (Allergy and Asthma Proc 26:
366 –372, 2005)
Bronchial hyperresponsiveness (BHR) usually is definedas an increased sensitivity of the airways to inhaled
nonsensitizing bronchoconstrictor stimuli.1 However, there
is accumulating evidence that BHR is a more complex
functional abnormality that comprises more than just in-
creased sensitivity.2 When exposed to high concentrations
of an agonist, normal subjects feature a maximal response
plateau on the dose–response curve at mild degrees of
airway narrowing, whereas asthmatic patients show an ex-
From the Department of Pediatrics, College of Medicine, Seoul
National University, Seoul, Korea
This study was supported in part by BK 21 Project for Medicine,
Dentistry, and Pharmacy and by Grant 21-2004-010-0 from the
Seoul National University Hospital Research Fund
Address correspondence and reprint requests to Young Yull Koh,
M.D., Department of Pediatrics, Seoul National University Hos-
pital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea
Copyright © 2005, OceanSide Publications, Inc., U.S.A.
366 September-October 2005, Vol. 26, No. 5
cessive airway narrowing, as reflected by either an elevated
or absent maximal response plateau. It has been argued that
excessive airway narrowing is clinically a more relevant
component of BHR than airway sensitivity, because it re-
flects the potential severity of airway obstruction in the
individual patients.3,4 Several studies2,5 have suggested that
the mechanisms underlying maximal airway response and
airway sensitivity differ, and that airway sensitivity is not an
adequate measure of maximal airway response.
BHR is routinely evaluated by measuring the dose or
concentration (PC20) of inhaled methacholine or histamine
that causes a 20% fall in forced expiratory volume in 1
second (FEV1).
6 However, bronchoprovocation tests that
use high concentrations of an agonist to measure the max-
imal airway response directly are not practical for routine
clinical purposes because of the risks inherent in producing
an excessive fall in FEV1. It has been suggested that a
percentage fall in forced vital capacity (FVC) measured at
the PC20 dose of inhaled agonist (FVC) is a potentially
useful clinical measure in asthmatic patients because it
provides indirect information about gas trapping and there-
fore the maximal airway response.7 However, no study has
been undertaken as to whether FVC is actually correlated
with the degree of maximal airway response.
The precise mechanism underlying BHR is still unclear,
although it is believed that airway inflammation plays a
major role.8 Eosinophils generally are viewed as being the
most important inflammatory cells.9 In asthma, the presence
of peripheral blood eosinophilia and increased serum levels
of eosinophilic granular proteins, such as eosinophil cat-
ionic protein (ECP), are well recognized.10 Investigators
increasingly are suggesting that serum ECP level may re-
flect the intensity of airway inflammation because it is
closely related to eosinophilic airway inflammation as eval-
uated by sputum or bronchoalveolar lavage samples.11,12
Several studies have examined the relationship between
serum ECP levels and airway sensitivity. Some13,14 have
found strong relationships, whereas in others15,16 these re-
lations were weak or absent. On the other hand, the rela-
tionship between serum ECP levels and the maximal airway
response or FVC is largely unknown. These are relevant
issues because airway eosinophilic inflammation has been
suggested to be related more closely to maximal airway
response than to airway sensitivity.17,18 The aims of this
study were to determine whether FVC is correlated with
the degree of maximal airway response and to examine the
relationship between serum ECP and FVC or maximal
airway response in patients who have mild asthma.
METHODS
Sixty-three children with mild asthma were recruitedfrom the allergy clinic at Seoul National University
Children’s Hospital. All subjects had a history of episodic
wheezing and/or dyspnea and had been diagnosed as having
asthma based on airway reversibility (an increase in FEV1
 15% after bronchodilator administration) or a methacho-
line PC20  16 mg/mL. In all cases asthma was mild, stable,
and controlled by bronchodilators on an as-needed basis,
with or without low-dose inhaled corticosteroids. Patients
with a history of near fatal asthma or major exacerbations
necessitating the use of systemic corticosteroids were ex-
cluded. Skin-prick tests were performed on all children to
evaluate atopic status. Atopy was defined as at least one
positive reaction (wheal size 3 mm) to 12 common air-
borne allergens. All subjects provided blood samples for the
determination of total eosinophil counts and serum ECP
levels, and all underwent high-dose methacholine challenge
tests. The patients stopped using inhaled bronchodilators or
other medications 48 hours before the study and inhaled
corticosteroids 7 days before the study. There was no his-
tory of upper respiratory infections for at least 4 weeks
before the study.
High-dose methacholine inhalation tests were performed
using a modification of the method described by Chai et
al.19 Spirometric measurements (FEV1 and FVC) were
made using a computerized spirometer (Microspiro-HI 298;
Chest, Tokyo, Japan), in accordance with the recommenda-
tions of the American Thoracic Society.20 The time course
of the preceding inspiration was standardized, i.e., rapid
maximal inspiration without an end-inspiratory pause, and
the FVC maneuver was continued until a pause in the forced
expired volume curve was obvious by visual inspection; the
minimum duration of the FVC maneuver was 6 seconds.
Subjects who were unable to perform spirometric tests
reproducibly or who had a low FEV1 (70% predicted)
21
were excluded. Methacholine (Sigma Diagnostics, St.
Louis, MO) solutions were prepared at different concentra-
tions (0.075, 0.15, 0.3, 0.625, 1.25, 2.5, 5, 10, 25, 50, 100,
150, and 200 mg/mL) in buffered saline solution (pH 7.4).
A Rosenthal-French dosimeter (Laboratory for Applied Im-
munology; Baltimore, MD), triggered by a solenoid valve
set to remain open for 0.6 seconds was used to generate the
aerosol from a DeVilbiss 646 nebulizer (DeVilbiss Health
Care, Somerset, PA), with pressurized air at 20 lb/in2. Each
subject inhaled five inspiratory capacity breaths of buffered
saline solution and increasing concentrations of methacho-
line at 5-minute intervals. This gave an output of 0.009 
0.0014 mL (mean  SD) per inhalation. FEV1 and FVC
were measured 60–90 seconds after inhalation at each con-
centration level, and the largest value of triplicate FEV1 or
FVC was used for analysis. The procedure was terminated
when the FEV1 level fell to 50% of the postsaline solution
value or when a maximal response plateau had been estab-
lished. This was considered to occur if three or more data
points at the highest concentrations fell within a 5% re-
sponse range.2 For safety reasons, subjects were given the
opportunity to discontinue challenge tests. Response, ex-
pressed as a percentage fall in FEV1 from the postsaline
solution value, was plotted against the log of the concen-
trations of inhaled methacholine. Dose–response curves
were characterized by their position and maximal response,
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the former expressed as PC20, which was calculated by
log-linear interpolation between two adjacent data points,
and the latter defined as the level of maximal response
plateau by averaging the consecutive points on the plateau.
The FVC relative to baseline FVC after saline inhalation
also was calculated using log-linear interpolation.
Blood samples were withdrawn using a 21-gauge butter-
fly needle with an attached syringe; care was taken to avoid
hemolysis. Eosinophil numbers were counted using an au-
tomated hematology analyzer (Coulter Counter, STKS;
Beckman Coulter, Fullerton, CA). Serum ECP measure-
ments were made according to the method of Venge.22
Blood samples (4 mL) were collected in Vacutainer SST
tubes (BD Biosciences, Franklin Lakes, NJ) and allowed to
stand for 60 minutes at room temperature. They were then
centrifuged at 1300  g for 10 minutes, and sera were
stored at 70°C until the ECP concentration was deter-
mined using an ECP radioimmunoassay kit (Amersham
Biosciences, Piscataway, NJ). All assays were performed in
duplicate, and mean values were used for statistical analy-
sis. The detection limit of the assay was 2 g/L, and the
intra-assay coefficient of variation was 6.8%. Parents gave
written informed consent for their children to participate in
the study. The study protocol was approved by the Hospital
Ethics Committee.
Statistical Analysis
The values of FEV1 and FVC are expressed as percent-ages of predicted based on data from our local pop-
ulation.21 PC20 values were logarithmically transformed
before analysis and are expressed as geometric means with
a range of 1 SD. Other values are presented as mean  1
SD. Values of subjects with and without a maximal re-
sponse plateau were compared using the Student’s t-test.
Correlation analyses were performed using Pearson corre-
lation coefficients. All analyses were made using Stat View
II (Abacus Concept, Inc., Berkeley, CA) on a Macintosh
computer (Apple Computer, Inc., Cupertino, CA). A value
of p  0.05 was considered statistically significant.
RESULTS
A total of 63 subjects were enrolled in the study. Ofthese, five were excluded due to test interruption
because of discomfort or dyspnea. Complete data were
available for 58 subjects. The mean  SD age was 11.2 
2.1 years with a male/female ratio of 1.9:1. Spirometric
values, results of high-dose methacholine challenge tests,
and blood eosinophil marker data are summarized in Table
I. Seventy-eight percent of the subjects were found to be
atopic and the majority (89%) of these developed a reaction
to house-dust mites. Two subjects had a methacholine PC20
above 16 mg/mL, which was defined as the BHR cutoff.
Twenty-five subjects featured a maximal response plateau
on their dose–response curve to methacholine.
A comparison of FVC in subjects with and without a
maximal response plateau is shown in Fig. 1 a. The FVC
was significantly higher in subjects without a plateau
(17.9  4.1%) than in those with a plateau (14.9  4.8%;
p  0.017). The relationship between FVC and the max-
imal response plateau level among subjects with a plateau is
shown in Fig. 1 b. There was a significant correlation be-
tween FVC and the maximal response plateau level (r 
0.446; p  0.026). Regression plots of FVC against
methacholine PC20 in all subjects are shown in Fig. 2. No
significant correlation was found between FVC and
methacholine PC20 (r  0.182; p  0.172). The relation-
ship between maximal airway response and methacholine
PC20 also was examined. Methacholine PC20 did not differ
significantly between subjects without a maximal response
plateau (geometric mean, 4.47 mg/mL [range of 1 SD,
1.51–13.18]) and those with a plateau (mean, 5.89 [range,
2.95–11.75]; p  0.242). No significant relationship was
found between methacholine PC20 and the maximal re-
sponse plateau level among subjects with a plateau (r 
0.220; p  0.291) (data not shown).
Serum ECP levels of subjects with and without a maxi-
mal response plateau are shown in Fig. 3 a. The serum ECP
level of subjects with a plateau was 28.0  12.3 g/L,
which was not significantly different from serum ECP lev-
els (32.5  24.5 g/L) in subjects without a plateau (p 
0.365). The relationship between serum ECP concentration
and the maximal response plateau level among subjects with
a plateau is shown in Fig. 3 b. There was no significant
correlation between serum ECP concentration and the max-
imal response plateau level (r  0.250; p  0.228). Regres-
sion plots of serum ECP levels against FVC in all subjects
are shown in Fig. 4. No significant correlation was found
between serum ECP levels and FVC (r  0.186; p 
0.163). The relationship between serum ECP levels and
methacholine PC20 also was examined, but no significant
correlation was found (r  0.185; p  0.166; data not
shown).
TABLE I
Summary of Spirometric Values, Results of High-Dose
Methacholine Challenge Tests, and the Values of
Blood Eosinophil Markers in All Subjects (n  58)
FEV1 (% predicted)* 94.7  9.5
FVC (% predicted)* 99.3  10.6
FEV1/FVC (%)* 85.4  5.1
Methacholine PC20 (mg/mL)# 5.00 (1.96–12.76)
Maximal response plateau
(%; n  25)*
41.1  6.1
FVC (%)* 16.6  4.6
Serum ECP (g/L)* 30.6  20.1
Total eosinophil count (/L)* 413.1  224.9
*Mean  SD.
#Geometric mean (range of 1 SD).
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DISCUSSION
This study shows that FVC is significantly correlatedwith the maximal airway response in patients who
have mild asthma. This substantiates the hypothesis that
FVC may reflect gas trapping because of excessive bron-
choconstriction. Neither maximal airway response nor
FVC had a relationship with serum ECP levels in patients
with mild asthma.
Excessive bronchoconstriction is presumably the most
important pathophysiological abnormality in asthma be-
cause it puts patients who have asthma at risk for serious
illness.3,4 Excessive bronchoconstriction is reflected by an
absent or elevated maximal response plateau on the metha-
choline dose–response curve.2 However, its measurement is
neither safe nor easy to perform, because of the problems
inherent in provoking an excessive fall in FEV1. Therefore,
a new means of quantifying excessive bronchoconstriction
is desirable. Gibbons et al.7 proposed a novel indirect
method for the detection of excessive bronchoconstriction
in patients with mild, newly diagnosed asthma. They retro-
spectively measured FVC, which reflects the gas trapped
at that point of dose–response curve caused by excessive
bronchoconstriction. Indeed, it has long been appreciated
that residual volume increases23 and vital capacity falls24
significantly in patients with asthma during induced bron-
choconstriction. Assuming that total lung capacity remains
constant,25 the gas trapping so induced should be easily
measurable as a dose-dependent fall in vital capacity. Un-
like the PC20, FVC was found significantly related to the
average number of oral corticosteroid prescriptions per
month, which suggests that it may be a more useful index of
disease severity in asthma than PC20. After this report,
several studies26,27 have indicated that FVC has potential
as a clinical marker in identifying patients with asthma at
risk for serious disease. However, the relationship between
FVC and the degree of excessive bronchoconstriction has
not been investigated to date.
In this study, mild asthma patients were selected because
a maximal response plateau usually is not measurable in
patients who have moderate to severe asthma, reflecting the
potential for excessive airway narrowing. Even in patients
with mild asthma, the plateau was not detectable in more
than one-half (56.9%) of the subjects, making the evaluation
of the correlation complicated. Given this reservation, asth-
Figure 1. (a) A comparison of FVC in subjects with and without a maximal response plateau (MRP). Horizontal bars represent mean 
SD. (b) The relationship between FVC and the maximal response plateau level among the subjects with a plateau.
Figure 2. Regression plots of FVC against methacholine PC20
in all subjects.
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matic patients without a maximal response plateau had a
higher value of FVC than asthmatic patients with a pla-
teau. Furthermore, in the latter group, a significant correla-
tion was found between the level of maximal response
plateau and FVC. These results substantiate the hypothesis
proposed by Gibbons et al.7 and suggest that FVC may be
used as a surrogate marker of maximal airway response in
patients with mild asthma. Thus, FVC has potential as a
clinically useful parameter because its measurement carries
no additional risk over that of a routine bronchial challenge
test and avoids the problems inherent in provoking an
excessive fall in FEV1. On the other hand, there was no
correlation between PC20 and FVC, which also was the
case in the patients described by other investigators.7,26,28
These results suggest that the ease of bronchoconstriction,
as reflected by the PC20, and the degree of gas trapping, as
reflected by the FVC, represent two distinctive responses
to methacholine inhalation.
It should be mentioned that the mean FVC of this study
is higher than those previously reported in adult asthmatic
patients.7,26 This is unlikely to be caused by differences in
disease severity because only patients with mild asthma
were included in this study. Children may be prone to
muscle weakness and fatigue, and it is possible that the
observed increase in FVC may be a consequence of a
reduction in FVC during bronchoprovocation testing,
caused by a progressive shortening in expiration leading to
incomplete emptying of the lungs. However, this can not be
the case, because compliance with the American Thoracic
Society criteria,20 including the occurrence of an expiratory
plateau, was checked on all occasions. Furthermore, the
minimum duration of FVC maneuver was 6 seconds. FEV
in 6 seconds has been suggested to be more reproducible
than FVC and to be an acceptable surrogate for FVC in the
diagnosis of airway obstruction.29 The effects of lung elastic
recoil on airway smooth muscle load play an important role
in determining the degree of bronchoconstriction.30 Cuttitta
et al.31 assumed that reduction in lung elastic recoil would
account for a higher level of FVC in elderly patients with
asthma. Pulmonary elastic recoil was reported to be at a
maximum in the late teens and decrease both with increas-
ing and decreasing age.32,33 We speculate that age-related
lung elasticity factors may result in enhanced bronchocon-
striction and thus a higher FVC.
Figure 3. (a) A comparison of serum ECP levels in subjects with and without a maximal response plateau (MRP). Horizontal bars represent
mean  SD. (b) The relationship between serum ECP concentration and the maximal response plateau level among the subjects with a
plateau.
Figure 4. Regression plots of serum ECP levels against FVC in
all subjects.
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Most published studies on the relationship between BHR
and serum ECP levels have treated airway hypersensitivity
as BHR. Some authors found significant correlations be-
tween methacholine PC20 and serum ECP levels,
13,14
whereas others failed to find such relationships.15,16 These
result discrepancies probably reflect the multifactorial na-
ture of airway hypersensitivity,34 components of which vary
between individuals, and therefore the results are strongly
influenced by subject selection. Relatively few studies have
examined the relationship between airway inflammation
and maximal airway response. In patients with allergic
rhinitis, Alvarez et al. reported that a higher degree of
sputum eosinophilia was detected in subjects without a
maximal response plateau35 and that the presence of eosin-
ophilia and the plateau level were significantly correlated.17
However, no such relationship was found between sputum
eosinophil count or ECP levels and methacholine PC20.
17
Moller et al. found that the number of activated eosinophils
in the bronchial mucosa was significantly related to the
maximal response plateau value but not to methacholine
PC20.
18 These results raise the possibility that maximal
airway response and implicitly FVC, rather than metha-
choline PC20, may be closely related to serum ECP levels.
In this study, not only methacholine PC20, but also max-
imal airway response or FVC, was found to be unrelated
to serum ECP levels. This suggests that maximal airway
response and FVC do not have a higher capacity than
bronchial sensitivity to discriminate blood eosinophil acti-
vation in mild asthma. This lack of correlation may be
explained in several ways. First, patients with mild asthma
were chosen for this study to detect a maximal response
plateau. Subjects with mild asthma may not represent a
whole spectrum of asthmatic patients and the small range of
values of the parameters could, at least partly, account for
our results. Second, the inflammatory process in asthma is
primarily localized in the airways; thus, correlations be-
tween the parameters of BHR and eosinophil activation may
be manifest in sputum or bronchoalveolar lavage fluid,
rather than in peripheral blood, as used in this study. Third,
a degree of airway remodeling, which can be found even in
mild and short-evolution asthma,36 would enhance BHR.
This component of BHR may not be associated with in-
creased serum ECP levels.
CONCLUSIONS
Patients with mild asthma without a maximal responseplateau had a higher FVC level than those with a
plateau. Furthermore, in this latter group, a significant cor-
relation was found between the plateau level and FVC.
These results suggest that FVC may be used as a surrogate
marker of maximal airway response in patients who have
mild asthma. Not only methacholine PC20, but also maximal
airway response or FVC, had no relationship with serum
ECP levels. This suggests that neither maximal airway
response nor FVC reflect blood eosinophil activation any-
more than methacholine PC20 in patients with mild asthma.
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